Our experts have written, co-written, and provided insights into hundreds of publications.
Ainutlaatuinen kokonaisuus – Lääketutkimuksen kehittäjät. Lääketeollisuus ry:n ilmoitusliite Kauppalehti Nov 21, 2012. Tulevaisuuden lääkkeet, p. 3. Yksi haastatelluista: Soini, E.
Fimean suositus lääkkeiden hoidollisen ja taloudellisen arvon arvioinnista (Fimea recommendation for the assessment of the therapeutic and economic value of pharmaceuticals). Fimea kehittää, arvioi ja informoi -julkaisusarja 2/2012 (Serial Publication Fimea Develops, Assesses and Informs 2/2012). Projektiryhmän jäsen / project team member: Martikainen, J.
Asseburg C, Soini E, et al. Cost-effectiveness and budget impact of certolizumab pegol against a mix of treatments in an outcomes-based risk-sharing scheme in Finland. Value Health 2012;15(7):A454.
Martikainen J, Soini E, et al. Economic impact of 13-valent pneumococcal conjugate vaccine (PCV13) in persons over 50 years of age with underlying chronic medical conditions in Finland. Value Health 2012;15(7):A388-9.
Soini E, Mäkirinne-Kallio N, Martikainen J et al. Estimation of quality-adjusted survival with mild obstructive sleep apnoea and six quality of life (QoL) assessments: Comparison between trapezoid rule, cross-sectional and mixed model estimates. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:158.
Soini E, Leussu M, Hallinen T. Administration costs of intravenous biologic drugs for rheumatoid arthritis: Discrepancy between list cost prices and published costs. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:223.
Soini EJ, Martikainen JA et al. Comparison of EQ-5D- and 15D-based quality-adjusted life-years (QALY) in patients with mild obstructive sleep apnoea (MOSA) using mixed modelling: Measurement tool and tariff matter. 14th Biennial Society for Medical Decision Making (SMDM) European Meeting, Oslo. Program and abstracts 2012:159.
Asseburg C. Uncertainty in computer simulation models. Economics, Modelling and Diabetes: The Sixth Mt Hood Challenge. Baltimore, USA, Jun 7-8, 2012.
Hallinen T, Soini E, et al. Cost-utility of tocilizumab in the treatment of systemic juvenile idiopathic arthritis in Finland. Annals of the Rheumatic Diseases 2013;71(Suppl3):258-9. Poster presented at the Annual European Congress of Rheumatology (EULAR) 2012, Berlin.
Hallinen T, Soini E, et al. Cost-effectiveness of insulin glargine compared to other long-acting basal insulins in the treatment of Finnish type 1 and type 2 diabetes patients based on individual studies. Dosis 2012;28:145-64.
Peura PK, Martikainen JA, et al. Sponsorship-Related Outcome Selection Bias in Published Economic Studies of Triptans: Systematic Review. Med Decis Making 2012;32(2):237-45.
Cummins E, Asseburg C, et al. Cost effectiveness of golimumab for the treatment of active psoriatic arthritis. Eur J Health Econ 2012;13(6):801-9.
Manca A, Asseburg C, et al. The Cost-Effectiveness of Different Chemotherapy Strategies for Patients with Poor Prognosis Advanced Colorectal Cancer (MRC FOCUS). Value Health 2012;15(1):22-31.
Hallinen T, Soini E, et al. Dabigatraanin kustannusvaikuttavuus eteisvärinäpotilaiden aivohalvausten ehkäisyssä. Dosis 2012;28:130-44.
Soini E, et al. Contingent Valuation of Eight New Treatments: What is the Clinician’s and Politician’s Willingness to Pay? The Open Complementary Medicine Journal 2012;4:1-11.
Soini E, Martikainen JA, et al. Economic evaluation of sequential treatments for follicular non-Hodgkin lymphoma. Clin Ther 2012;34(4):915-25.
Asseburg C, et al. Hospitalisation utilisation and costs in schizophrenia patients in Finland before and after switch to risperidone long-acting injection. Schizophr Res Treatment 2012; 2012: 791468.
Soini E, Hallinen TA, et al. Cost-effectiveness of adalimumab, etanercept and tocilizumab as first-line treatments for moderate-to-severe rheumatoid arthritis. J Med Econ 2012;15(2):340-51.
Martikainen J, Asseburg C, et al. Triptaanien kustannusvaikuttavuus akuutin migreenikohtauksen hoidossa. Lääkealan turvallisuus- ja kehittämiskeskus Fimea. Fimea kehittää, arvioi ja informoi –julkaisusarja 1/2011.
GAO. Value in Health Care. Key Information for Policymakers to Assess Efforts to Improve Quality While Reducing Costs. Washington: United States Government Accountability Office’s Report to Congressional Requesters, 2011. One of the responders: Soini, E.
Soini E. Harvinaissairauksien taloudellinen arviointi: mitä päätöksien tueksi tulisi tuottaa? Harvinaiset Sairaudet -lehti 2011;1:26-31.
Peura P, Turunen J, Purmonen T, Happonen P, Martikainen J. Mitä lääkehoitojen kustannusvaikuttavuus tarkoittaa? Sic! 2/2011
Ramsberg J, Asseburg C, Henriksson M. Effectiveness and cost-effectiveness of antidepressants in primary care -a multiple treatment comparison meta-analysis and cost-effectiveness model. PLoS One 2012;7(8):e42003.
Hallinen T, Soini E, et al. Differential use of extended and immediate release quetiapine: A retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012;2(4):e000915.
Asseburg C, Peura P, Oksanen T, Turunen J, Purmonen T, Martikainen J. Cost-effectiveness of oral triptans for acute migraine: mixed treatment comparison. Int J Technol Assess Health Care 2012;28(4):382-9.
Soini E. Terveystaloustrendiksi todellisen hoitotilanteen kustannusvaikuttavuus. Impulssi 2011;3:16-7.
Soini E. Myytkö lisäkustannuksia vai kustannusvaikuttavuutta? Podium 2011;5:19.
Kokonaisuus ratkaisee kustannusvaikuttavuuden. BI News 2011;syksy. Suomen Lääkärilehden välissä julkaistu tiedotuslehtinen. Haastateltu: Soini, E.
Willis M, Asseburg C, He J. Validation of Economic Simulation Models Using Clinical Trial Results: Experiences from Type 2 Diabetes Mellitus (T2DM). iHEA 2011. Podium. J Med Econ 2013;16(8):1007-21.
Willis M, Neslusan C, Asseburg C, et al. Initial HbA1c and HbA1c Lowering: Implications for Model-Based Economic Evaluations in Type 2 Diabetes Mellitus (T2DM). American Diabetes Association (ADA) meeting 2011. Podium.